MET and breast cancer: Lau et al. demonstrated that paclitaxel exhibits antiangiogenic activity by downregulating VEGF in a highly vascularized transgenic murine Met-1 breast cancer model, administered at non-cytotoxic doses, paclitaxel significantly reduced intratumoral angiogenesis and also suppressed VEGF expression in the tumors [32].